NasdaqCM - Delayed Quote USD

Catalyst Pharmaceuticals, Inc. (CPRX)

14.68 -0.44 (-2.91%)
At close: April 25 at 4:00 PM EDT
14.60 -0.08 (-0.54%)
Pre-Market: 8:07 AM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Richard John Daly M.B.A. President, CEO & Director 68.12k -- 1961
Dr. Steven R. Miller Ph.D. Executive VP, COO & Chief Scientific Officer 884.7k -- 1962
Dr. Gary Ingenito M.D., Ph.D. Chief Medical & Regulatory Officer 811.39k -- 1956
Mr. Jeffrey Del Carmen Executive VP & Chief Commercial Officer 799.82k -- 1971
Mr. Michael W. Kalb CPA Executive VP, Treasurer & CFO -- -- 1971
Ms. Mary Coleman VP & Head of Investor Relations -- -- --
Mr. Brian Elsbernd J.D. Chief Compliance Officer & Chief Legal Officer 311.42k -- 1964
Mr. Pete Curry Sr. Vice President of Sales -- -- --
Dr. Stanley Iyadurai M.D., Ph.D. Senior Vice President of Medical Affairs & Drug Discovery -- -- --
Dr. Preethi Sundaram Ph.D. Chief Strategy Officer 511.25k -- 1976

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200 https://www.catalystpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
167

Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 3; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024
Catalyst Pharmaceuticals, Inc. Earnings Call

Related Tickers

AXSM Axsome Therapeutics, Inc.
71.52
+0.49%
 
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
 
ARDX Ardelyx, Inc.
6.31
-1.87%
 
HALO Halozyme Therapeutics, Inc.
38.46
-1.69%
 
XFOR X4 Pharmaceuticals, Inc.
1.1300
-12.40%
 
LGND Ligand Pharmaceuticals Incorporated
70.37
-0.89%
 
EWTX Edgewise Therapeutics, Inc.
15.94
-1.06%
 
AUPH Aurinia Pharmaceuticals Inc.
4.8700
-3.18%
 
OCUP Ocuphire Pharma, Inc.
1.5350
+0.33%
 
VNDA Vanda Pharmaceuticals Inc.
4.4800
-1.75%